Evidence map›Paper›PMID 30938035›Full record

Trial reportDiabetes, obesity & metabolism2019

Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial.

Wenying Yang, Jianhua Ma, Guoyue Yuan, Ling Li, Min Zhang, Yibing Lu, Xinhua Ye, Weihong Song, Ming Liu, Jun Wu and 5 more

Erratum issuedAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Wenying YangEndocrine Department, China-Japan Friendship Hospital, Beijing, China.ORCID 0000-0002-7997-9404
Jianhua MaEndocrine Department, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Guoyue YuanEndocrine Department, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Ling LiEndocrine Department, Shengjing Hospital of China Medical University, Shenyang, China.
Min ZhangEndocrine Department, Qingpu Branch of Zhongshan Hospital, Affiliated with Fudan University, Shanghai, China.
Yibing LuEndocrine Department, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Xinhua YeEndocrine Department, Changzhou Second People's Hospital, Affiliated with Nanjing Medical University, Changzhou, China.
Weihong SongEndocrine Department, Chenzhou No. 1 People's Hospital, Chenzhou, China.
Ming LiuEndocrine Department, Tianjin Medical University General Hospital, Tianjin, China.
Jun WuEndocrine Department, The Third Hospital of Wuhan, Wuhan, China.
Riqiu ChenEndocrine Department, Lishui People's Hospital, Lishui, China.
Yunguang LiMedical Department, Sanofi Investment Co., Ltd., Shanghai, China.
Xia ZhangMedical Department, Sanofi Investment Co., Ltd., Shanghai, China.
Nan CuiMedical Department, Sanofi Investment Co., Ltd., Shanghai, China.
Jinkui YangEndocrine Department, Beijing Tongren Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal fasting blood glucose (FBG) target of achieving HbA1c less than 7.0% in type 2 diabetes (T2D) patients remains controversial. This open-label trial randomized (1:3:3) 947 adults with uncontrolled T2D (HbA1c >7% to ≤10.5%) who were using one to three oral antidiabetic drugs to achieve an FBG target of 3.9 < FBG ≤5.6 mmol/L (Group 1), 3.9 < FBG ≤6.1 mmol/L (Group 2) or of 3.9 < FBG ≤7.0 mmol/L (Group 3). Targets were achieved using a pre-defined insulin glargine 100 U/mL titration scheme. The primary endpoint was proportion of patients achieving HbA1c <7.0% at 24 weeks. At 24 weeks, 44.4%, 46.1% and 37.7% of patients achieved HbA1c <7.0% in Groups 1, 2 and 3, respectively (P = 0.017; Group 2 vs Group 3). Alert hypoglycaemia (glucose ≤3.9 mmol/L) was significantly more frequent in Group 1 than in Group 3 (38.9 vs 23.3%; P < 0.001) but was not in Group 2 vs Group 3 (27.5% vs 23.3%; P = 0.177). Clinically important hypoglycaemia (glucose ≤3.0 mmol/L) was reported in 4.8%, 2.0% and 3.8% of patients in Groups 1, 2 and 3, respectively. In conclusion, the optimal FBG target for most Chinese patients with T2D appears to be 3.9-6.1 mmol/L.

Indexed as

AdultBlood GlucoseDiabetes Mellitus, Type 2FastingFemaleGlycated HemoglobinGoalsHumansHypoglycemiaHypoglycemic AgentsInsulin GlargineMaleMiddle AgedReference ValuesTreatment OutcomeBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin Glarginefasting blood glucoseglycated haemoglobininsulin glarginetype 2 diabetes

Identifiers

PMID30938035
PMCPMC6772047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.